Analysts Set Insmed, Inc. (NASDAQ:INSM) Price Target at $210.95

Shares of Insmed, Inc. (NASDAQ:INSM) have earned a consensus recommendation of “Moderate Buy” from the twenty-five brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, twenty-three have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $210.9545.

Several brokerages recently commented on INSM. Jefferies Financial Group began coverage on shares of Insmed in a research report on Monday, March 16th. They set a “buy” rating and a $228.00 price objective on the stock. HC Wainwright reissued a “buy” rating on shares of Insmed in a research report on Friday, May 8th. Truist Financial cut their price objective on shares of Insmed from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Stifel Nicolaus increased their price objective on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, Mizuho increased their price objective on shares of Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a research report on Wednesday, March 25th.

Insmed Stock Up 2.5%

NASDAQ:INSM opened at $108.87 on Friday. The firm’s 50-day moving average price is $136.61 and its 200-day moving average price is $159.60. The company has a market capitalization of $23.60 billion, a PE ratio of -18.93 and a beta of 0.89. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. Insmed has a 1-year low of $65.56 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. During the same period in the prior year, the firm earned ($1.42) EPS. The company’s revenue was up 229.7% compared to the same quarter last year. On average, equities analysts predict that Insmed will post -2.52 EPS for the current fiscal year.

Insider Activity at Insmed

In related news, insider Michael Alexander Smith sold 6,149 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $108.47, for a total transaction of $666,982.03. Following the sale, the insider directly owned 41,613 shares of the company’s stock, valued at approximately $4,513,762.11. This represents a 12.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the sale, the chief operating officer directly owned 106,810 shares in the company, valued at $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 156,643 shares of company stock valued at $24,513,766. 2.10% of the stock is owned by insiders.

Institutional Trading of Insmed

Institutional investors have recently made changes to their positions in the stock. CoreCap Advisors LLC purchased a new stake in shares of Insmed during the 4th quarter valued at about $27,000. Reflection Asset Management purchased a new stake in shares of Insmed during the 4th quarter valued at about $30,000. GraniteShares Advisors LLC purchased a new stake in shares of Insmed during the 4th quarter valued at about $30,000. CIBC Private Wealth Group LLC boosted its holdings in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the last quarter. Finally, Raiffeisen Bank International AG purchased a new stake in shares of Insmed during the 4th quarter valued at about $32,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.